A patent foramen ovale (PFO) as shown in
The cause of ischemic stroke remains cryptogenic (of unknown origin) in approximately 40% of cases. Especially in young patients, paradoxical embolism via a PFO is considered in the diagnosis. While there is currently no proof for a cause-effect relationship, many studies have confirmed a strong association between the presence of a PFO and the risk for paradoxical embolism or stroke. In addition, there is good evidence that patients with PFO and paradoxical embolism are at increased risk for future, recurrent cerebrovascular events.
The presence of a PFO has no therapeutic consequence in otherwise healthy adults. In contrast, patients suffering a stroke or transient ischemic attack (TIA) in the presence of a PFO and without another cause of ischemic stroke are considered for prophylactic medical therapy to reduce the risk of a recurrent embolic event. These patients are commonly treated with oral anticoagulants, which have the potential for adverse side effects, such as hemorrhaging, hematoma, and interactions with a variety of other drugs.
In certain cases, such as when anticoagulation is contraindicated, surgery may be used to close the PFO. To suture a PFO closed requires attachment of septum secundum to septum primum with either an interrupted or a continuous stitch, which is the common way a surgeon shuts the PFO under direct visualization.
Nonsurgical closure of PFOs has become possible with the advent of umbrella devices and a variety of other similar mechanical closure designs, developed initially for percutaneous closure of atrial septal defects (ASD). These devices allow patients to avoid the potential side effects often associated with anticoagulation therapies.
Currently available designs of septal closure devices, however, present such drawbacks as technical complexity of implantation procedure, high complication rates (thrombus, fractures, conduction system disturbances, perforations, residual leaks), high septal profile, large masses of foreign material, and lack of anatomic conformability especially to the PFO flap-like anatomy, as most were originally designed to close ASD's, which are true holes. Additionally, some septal closure devices are complex to manufacture, which can result in lack of consistency in product performance.
In one aspect, the present invention provides a method of closing two overlapping layers of tissue in a mammalian heart, e.g., a patent foramen ovale (PFO), using a closure device that applies a compressive force to at least one of the layers of tissue. The closure device may be retrievable, such that it may be removed after a period of time sufficient to allow the overlapping layers of tissue to fuse together. If necessary to sufficiently close the length of the layers of tissue, multiple closure devices may be administered. The closure devices may be delivered with a catheter capable of puncturing mammalian tissue in at least one location.
The closure device of the present invention may take a number of different forms. For example, the closure device may have first and second ends, both of which may be capable of puncturing mammalian tissue. The device may be a structure such as a ring with a gap, a folded ring, at least one grappling hook member joined to at least one curved arm by a joinder member, opposed grappling hook members joined by a central connecting member, a grappling hook member and a central connecting member, or a closure device anchor joined to a structure of sufficient diameter to hold the device in place against the overlapping layers of tissue. In some embodiments of the present invention, the closure device is sized and shaped such that it extends from septum secundum in the left atrium, into the left atrium, through septum primum, into the right atrium, and to septum secundum in the right atrium. Some retrievable devices include elongate tethers to facilitate their removal. Each of these devices has certain advantages, and one skilled in the art will be capable of selecting the device appropriate for a given application.
The ends of the closure device may also take a number of different forms. For example, at least one end may form a disc or a closure device anchor, such as a coil, hook, or corkscrew. These end structures help to maintain the device in place. One of the ends, for example the second end, may take the form of a knot or a structure similarly capable of holding the device in place and applying a sufficient compressive force to the overlapping layers of tissue. In some embodiments, the end structure may be adjusted to alter the compressive force applied to the overlapping layers of tissue. As previously mentioned, either or both of the first and second ends may be capable of puncturing mammalian tissue. In some embodiments, the first end of the device is a septal puncture needle.
The closure device may be formed of any of several materials, such as flexible polymer materials, bioabsorbable materials, shape memory materials, metals, noble metals, or swellable foams. In particular embodiments, the device includes nitinol. Some of the devices are formed from a single piece of material, while others are formed from multiple pieces of material joined together.
Some closure devices according to the present invention are intended to puncture septum primum upon insertion into the heart. For example, such a device may be inserted into the right atrium of the heart and puncture septum primum to enter the left atrium of the heart. At this point, the first end of the device may simply be deployed into the left atrium, or the first end of the device may be deployed into the left atrium and at least partially puncture septum secundum. In those embodiments where the first end of the device at least partially punctures septum secundum, the first end may be embedded in septum secundum or may completely puncture septum secundum such that the first end extends into the right atrium. The second end of the device may then be positioned against septum secundum in the right atrium, thereby providing a compressive force to the septal tissues. In other embodiments, the second end is also positioned in the left atrium while another portion of the device, such as a fold, is positioned in the right atrium, thereby compressing the septal tissues between the device.
Alternatively, some closure devices according to the present invention are intended to be inserted between the overlapping layers of tissue, e.g. through the PFO tunnel, to enter the left atrium. In these embodiments, the first end of the device is then deployed in the left atrium and the second end of the device is deployed in the right atrium, thereby providing a compressive force to the septal tissue. As discussed above, at least one of the ends of the device may partially puncture septum secundum.
These and other features will become readily apparent from the following detailed description wherein embodiments of the invention are shown and described by way of illustration.
a, 3b and 3c illustrate the steps in the deployment of the PFO closure device of
a, 5b and 5c illustrate the steps in the deployment of the PFO closure device of
a, 10b and 10c illustrate the steps in the deployment of a rivet and suture type of PFO closure device;
a, 11b, 11c and 11d illustrate the steps in the deployment of a removable PFO closure device;
a, 12b and 12c illustrate the steps in the deployment of a multiple hook PFO closure device;
a, 15b, and 15c are an end face view from the right atrium, an end face view from the left atrium, and a side elevation view, respectively, of the deployed alternative structure of the second embodiment of the PFO closure device with mechanical anchors of the present invention.
Referring to
To deploy the PFO closure device 18, the catheter 38 is inserted from the right atrium 10 through the PFO tunnel, i.e. between septum primum 14 and septum secundum 16, into the left atrium 12. As shown in
The grappling hook members 20 and 22 may be formed of flexible, spring-like, bioabsorbable polymer material so as to permit movement from the compressed straight shape to the curved hook shapes following deployment from the catheter 38. The central connecting member 24 may also be formed of bioabsorbable material, such as an absorbable suture material, so the device will ultimately leave no foreign substance in either atrium. Alternatively, the grappling hook members 20 and 22 may be formed of spring metal or of a shape memory material, such as nitinol. When the PFO closure device is not formed of bioabsorbable material, it is possible to form the device with only the grappling hook member 20 and a central connecting member 24 so that the device is repositionable and retrievable. When the device is made of a bioabsorbable material or is not intended to be retrievable, the ends of grappling hooks 26, 28, 30, 32, 34 and 36 may further include a barb to maintain the device in the septal tissue. In some embodiments, the grappling hook members 20 and 22 serve as tissue scaffolds, and are covered with a vascular material, such as polyester, biological tissue, bioresorbable polymer, or spongy polymeric material.
As shown in
As shown in
Multiple PFO closure devices 40, 90 or 100 can be inserted until the physician is satisfied with the resultant PFO closure. Again, the PFO closure devices may be formed of flexible, bioabsorbable polymer material, spring metal, other spring-like non-bioabsorbable material, or shape memory material. The choice of material will affect the degree to which the device conforms to the surrounding septal tissue. As shown in
A PFO may also be closed with one or more sutures. As used in the art and indicated in the Figures, “suture” refers to a single connection used to hold two pieces of material or tissue together and need not be a continuous stitch. However, to suture a PFO closed has conventionally required the attachment of septum secundum to septum primum with a continuous stitch. This need for a continuous stitch can be eliminated by implanting sutures across the PFO using implantable suture anchors. As shown in
The anchors are most likely fabricated from a shape memory alloy, such as nitinol, although they could be made from a flexible, bioabsorbable polymer or a noble metal, each having their own advantage—no long term implant issues with bioabsorbable anchors and excellent radiopacity with anchors fabricated from a noble metal, such as platinum-iridium. The remainder of the suture may be formed of any suitable material, including wire, polymeric materials, and bioabsorbable materials.
The suturing method includes using a standard septal puncture technique to locate and puncture septum primum. Following this, several approaches exist. One would be that the septal puncture needle would be withdrawn from the catheter and the suturing system then delivered through the catheter (the septal needle catheter would maintain position across septum primum during the exchange). Alternatively, a wire could be placed through the septal needle catheter to maintain position and the suture system could be delivered over the wire, or the septal puncture needle could become part of the suture system. Following delivery of the suture system, the proximal end of the suture may then be tied off so as to secure the system in place and keep the PFO closed. As described below for the rivet design suture system and shown in
In
In those cases where a true puncture through septum secundum can be made, an anchor can be placed entirely in the right atrium, leaving nothing but suture in the left atrium. These anchors may be short strips or cylindrical rods made from a metallic or polymeric material that is biostable or bioabsorbable, or a piece of swellable foam, such as Ivalon.
In another embodiment, the septal needle catheter crosses septum secundum in multiple locations simultaneously. In this embodiment, the final result, as seen from the left atrium in an end face view of septum primum and septum secundum, would be as shown in
A rivet design suture system 60 is shown in
The PFO closure device of the present invention may be formed in a manner to facilitate removal once septum primum and septum secundum are fused. An exemplary removable PFO closure device 70 is deployed in the manner illustrated by
To deploy the removable PFO closure device 70 according to one embodiment of the invention, the grappling hook member 74 is passed through septum primum 14 (
Once the PFO closure device 70 is in place, the catheter 72 is withdrawn and the free end of the tether 80 is attached to a button subcutaneously and allowed to remain in place for a period of time sufficient to allow the two septa to fuse together. Then the device is pulled through septum primum and into a recovery sheath by means of the tether 80 and removed.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
3875648 | Bone | Apr 1975 | A |
4006747 | Kronenthal et al. | Feb 1977 | A |
4007743 | Blake | Feb 1977 | A |
4425908 | Simon | Jan 1984 | A |
4696300 | Anderson | Sep 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4902508 | Badylak et al. | Feb 1990 | A |
4915107 | Rebuffat et al. | Apr 1990 | A |
4917089 | Sideris | Apr 1990 | A |
4956178 | Badylak et al. | Sep 1990 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5037433 | Wilk et al. | Aug 1991 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5108420 | Marks | Apr 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5236440 | Hlavacek | Aug 1993 | A |
5257637 | El Gazayerli | Nov 1993 | A |
5275826 | Badylak et al. | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5284488 | Sideris | Feb 1994 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5312341 | Turi | May 1994 | A |
5312435 | Nash et al. | May 1994 | A |
5334217 | Das | Aug 1994 | A |
5354308 | Simon et al. | Oct 1994 | A |
5411481 | Allen et al. | May 1995 | A |
5413584 | Schulze | May 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5480424 | Cox | Jan 1996 | A |
5486193 | Bourne et al. | Jan 1996 | A |
5507811 | Koike et al. | Apr 1996 | A |
5540712 | Kleshinski et al. | Jul 1996 | A |
5577299 | Thompson et al. | Nov 1996 | A |
5601571 | Moss | Feb 1997 | A |
5618311 | Gryskiewicz | Apr 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5626599 | Bourne et al. | May 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5649950 | Bourne et al. | Jul 1997 | A |
5683411 | Kavteladze et al. | Nov 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5702421 | Schneidt | Dec 1997 | A |
5709707 | Lock et al. | Jan 1998 | A |
5720754 | Middleman et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5733337 | Carr, Jr. et al. | Mar 1998 | A |
5741297 | Simon | Apr 1998 | A |
5776162 | Kleshinski | Jul 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5810884 | Kim | Sep 1998 | A |
5823956 | Roth et al. | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5861003 | Latson et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5893856 | Jacob et al. | Apr 1999 | A |
5902319 | Daley | May 1999 | A |
5904703 | Gilson | May 1999 | A |
5919200 | Stambaugh et al. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5989268 | Pugsley, Jr. et al. | Nov 1999 | A |
5993475 | Lin et al. | Nov 1999 | A |
5993844 | Abraham et al. | Nov 1999 | A |
5997575 | Whitson et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6030007 | Bassily et al. | Feb 2000 | A |
6056760 | Koike et al. | May 2000 | A |
6077291 | Das | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6096347 | Geddes et al. | Aug 2000 | A |
6106913 | Scardino et al. | Aug 2000 | A |
6113609 | Adams | Sep 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6171329 | Shaw et al. | Jan 2001 | B1 |
6174322 | Schneidt | Jan 2001 | B1 |
6187039 | Hiles et al. | Feb 2001 | B1 |
6206895 | Levinson | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6214029 | Thill et al. | Apr 2001 | B1 |
6217590 | Levinson | Apr 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6228097 | Levinson et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6245080 | Levinson | Jun 2001 | B1 |
6265333 | Dzenis et al. | Jul 2001 | B1 |
6270515 | Linden et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6287317 | Makower et al. | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6306150 | Levinson | Oct 2001 | B1 |
6306424 | Vyakarnam et al. | Oct 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6319263 | Levinson | Nov 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6334872 | Termin et al. | Jan 2002 | B1 |
6342064 | Koike et al. | Jan 2002 | B1 |
6344049 | Levinson et al. | Feb 2002 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6348041 | Klint | Feb 2002 | B1 |
6352552 | Levinson et al. | Mar 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6364853 | French et al. | Apr 2002 | B1 |
6375625 | French et al. | Apr 2002 | B1 |
6375671 | Kobayashi et al. | Apr 2002 | B1 |
6379342 | Levinson | Apr 2002 | B1 |
6379368 | Corcoran et al. | Apr 2002 | B1 |
6387104 | Pugsley, Jr. et al. | May 2002 | B1 |
6398796 | Levinson | Jun 2002 | B2 |
6402772 | Amplatz et al. | Jun 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6440152 | Gainor et al. | Aug 2002 | B1 |
6460749 | Levinson et al. | Oct 2002 | B1 |
6482224 | Michler et al. | Nov 2002 | B1 |
6488706 | Solymar | Dec 2002 | B1 |
6494888 | Laufer et al. | Dec 2002 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551344 | Thill | Apr 2003 | B2 |
6596013 | Yang et al. | Jul 2003 | B2 |
6623508 | Shaw et al. | Sep 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6666861 | Grabek | Dec 2003 | B1 |
6712804 | Roue et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20010034537 | Shaw et al. | Oct 2001 | A1 |
20010037129 | Thill | Nov 2001 | A1 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010044639 | Levinson | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020010481 | Jayaraman | Jan 2002 | A1 |
20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
20020026208 | Roe et al. | Feb 2002 | A1 |
20020029048 | Miller | Mar 2002 | A1 |
20020032462 | Houser et al. | Mar 2002 | A1 |
20020035374 | Borillo et al. | Mar 2002 | A1 |
20020043307 | Ishida et al. | Apr 2002 | A1 |
20020052572 | Franco et al. | May 2002 | A1 |
20020077555 | Schwartz | Jun 2002 | A1 |
20020096183 | Stevens et al. | Jul 2002 | A1 |
20020099389 | Michler et al. | Jul 2002 | A1 |
20020107531 | Schreck et al. | Aug 2002 | A1 |
20020111637 | Kaplan et al. | Aug 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020120323 | Thompson et al. | Aug 2002 | A1 |
20020128680 | Pavlovic | Sep 2002 | A1 |
20020129819 | Feldman et al. | Sep 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020183786 | Girton | Dec 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020183823 | Pappu | Dec 2002 | A1 |
20020198563 | Gainor et al. | Dec 2002 | A1 |
20030028213 | Thill et al. | Feb 2003 | A1 |
20030045893 | Ginn | Mar 2003 | A1 |
20030050665 | Ginn | Mar 2003 | A1 |
20030059640 | Marton et al. | Mar 2003 | A1 |
20030065379 | Babbas et al. | Apr 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030139819 | Beer et al. | Jul 2003 | A1 |
20030191495 | Ryan et al. | Oct 2003 | A1 |
20030195530 | Thill | Oct 2003 | A1 |
20030204203 | Khairkhahan et al. | Oct 2003 | A1 |
20040044361 | Franzier et al. | Mar 2004 | A1 |
20040210301 | Obermiller | Oct 2004 | A1 |
Number | Date | Country |
---|---|---|
1 013 227 | Jun 2000 | EP |
1 046 375 | Oct 2000 | EP |
1 222 897 | Jul 2002 | EP |
WO 9625179 | Aug 1996 | WO |
WO 9631157 | Oct 1996 | WO |
WO 0027292 | May 2000 | WO |
WO 0044428 | Aug 2000 | WO |
WO 0149185 | Jul 2001 | WO |
WO 0224106 | Mar 2002 | WO |
WO 03077733 | Sep 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20030144694 A1 | Jul 2003 | US |
Number | Date | Country | |
---|---|---|---|
60347336 | Jan 2002 | US |